[Seeing a new classification of active medications in psychoses].
Costentin
J
J
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000145:classification*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use*; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011618:Psychotic Disorders / Q000188:drug therapy*; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors; D011976:Receptors, Muscarinic / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D013881:Thioridazine / Q000009:adverse effects / Q000627:therapeutic use
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D050637:Receptors, Dopamine D3; D011976:Receptors, Muscarinic; D011985:Receptors, Serotonin; D013881:Thioridazine; D002746:Chlorpromazine